DISPENDIX, a BICO company, announces the appointment of Petros Apostolopoulos as the new company CEO. Petros will lead product, growth, market expansion and overall business operations and will continue to drive the strategy and focus of DISPENDIX to deliver customer success.

Before joining DISPENDIX, Petros served over 15 years at Festo, a global leader in automation technology, where he was responsible for the Liquid Handling portfolio and created and implemented strategy, R&D and operations and built teams in Germany, U.S., and Brazil.

In 2016, DISPENDIX was founded as a spin-off from the Fraunhofer Institute for Manufacturing Engineering and Automation in Stuttgart, Germany. The company was built with the vision to establish an affordable innovative technology in non-contact liquid handling. Today, DISPENDIX has grown a global customer base across research, academia and pharmaceuticals.

I am thrilled to be joining the dynamic and talented DISPENDIX team”, says Petros Apostolopoulos, DISPENDIX CEO. “DISPENDIX has already set new standards in low volume dispensing with its groundbreaking drop-on-demand technology. In the next phase of our business, we will work with our customers to create the future of health through new liquid handling technologies.

Since its founding in 2016, BICO has strategically been building an expansive portfolio of Life Science products that spans bioprinting, diagnostics, lab automation, biosciences, and other key verticals. Its devices are already being used in more than 2,000 labs across 65 countries – including Harvard, Stanford, Roche, Merck, Novartis, J&J, AstraZeneca, and others. As a BICO company, DISPENDIX is furthering its bio convergence agenda by merging key technologies to improve human health. Since joining BICO, DISPENDIX has grown more than 1,000%.

There is no better person than Petros to grow the DISPENDIX ecosystem and advance its mission of creating the future of health through liquid handling and lab automation”, says BICO CEO and co-founder Erik Gatenholm. “His strong experience in the field will help the entire team advance life-saving drug discovery and diagnostics technologies.

Companies interested in partnering or using DISPENDIX’s liquid handling or lab automation devices can find more information at dispendix.com.

For further information, please contact:

Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
Email: il@bico.com    
BICO Press office 
Phone (US):
Riley Munks, PR Manager: (650) 863-6699
Alyssa D’Orazio, PR Manager: (617) 634-9601

Email: press@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on August 23, 2021, at 8am (CEST).

About DISPENDIX
DISPENDIX GmbH, the premier provider of noncontact liquid handling solutions in the nano to microliter range, started out in 2016 as a spin-off from the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) in Stuttgart, Germany.

In 2018, DISPENDIX joined the world’s leading bio convergence company BICO, which now encompasses 900+ colleagues and 11 companies, offering a portfolio of technologies, products and services to create the future of health. Part of that portfolio is DISPENDIX’s patented and widely recognized technology, the I.DOT (Immediate Drop-on-demand Technology), which brings intuitive automation, precision and speed to every lab, allowing scientists to optimize liquid handling workflows and accelerate their research in a range of applications.

DISPENDIX’S Liquid handling technology enables new discoveries in areas such as drug development, diagnostics and synthetic biology. We believe that technological advances and science are made for each other. Good technology simplifies science. www.dispendix.com

About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,850 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com